Brief: Finch Therapeutics Presents Positive Data From Mid-Stage Trial Of CP101 For Recurrent C. Difficile At American College Of Gastroenterology Annual Scientific Meeting
25/10/2021 12:43
Oct 25 (Reuters) - Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS PRESENTS POSITIVE DATA FROM PRISM3
CLINICAL
TRIAL OF CP101 FOR RECURRENT C. DIFFICILE AT AMERICAN COLLEGE OF
GASTROENTEROLOGY ANNUAL SCIENTIFIC MEETING
* FINCH THERAPEUTICS GROUP INC - CP101 DEMONSTRATED EFFICACY
THROUGH WEEK 24
* FINCH THERAPEUTICS GROUP INC - CP101 EXHIBITED A FAVORABLE
SAFETY PROFILE THROUGH WEEK 24
Source text for Eikon: ID:nGNXbjbTq5
Further company coverage: FNCH.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp